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Alternative splicing of the IgIII loop of ﬁbroblast growth factor receptors (FGFRs) 1–3 produces b- and c-variants of the receptors
withdistinctlydiﬀerentbiologicalimpactbasedontheirdistinctligand-bindingspectrum.Tissue-speciﬁcexpressionofthesesplice
variantsregulatesinteractionsinembryonicdevelopment,tissuemaintenanceandrepair,andcancer.AlterationsinFGFR2splicing
are involved in epithelial mesenchymal transition that produces invasive, metastatic features during tumor progression. Recent
research has elucidated regulatory factors that determine the splice choice both on the level of exogenous signaling events and on
the RNA-protein interaction level. Moreover, methodology has been developed that will enable the in depth analysis of splicing
events during tumorigenesis and provide further insight on the role of FGFR 1–3 IIIb and IIIc in the pathophysiology of various
malignancies.Thispaperaimstosummarizeexpressionpatternsinvarioustumortypesandoutlinespossibilitiesforfurtheranaly-
sis and application.
1.Introduction
Fibroblast growth factors (FGFs) are a large family of 23 lig-
ands that serve crucial functions in embryonic development
as well as in the adult organisms (for review see [1]). They
mediate their signals via a small subfamily of 4 tyrosine
kinase receptors (FGFR 1–4). This is a small number of
receptors for a large group of ligands, but the system gains
signiﬁcant complexity from the formation of heterodimers
as well as a high frequency of alternative splicing events [2, 3]
that can be grouped in 3 categories. These categories are (1)
the deletion of autoinhibitory domains close to the N- or the
C-terminus of the proteins which produces more active and
frequently oncogenic receptorvariants [4, 5], (2) the IIIb and
IIIc variants which are produced by alternative exon usage in
the ligand-binding domain [2], and (3) soluble variants that
come from exclusion of the exon that codes for the trans-
membrane region [6, 7]. All of these molecules display dis-
tinct biological activities. The IIIb and IIIc variations have
been described for FGFRs 1–3 and probably have the stron-
gest impact as they alter the ligand-binding portion of the
aﬀected FGFR [8]. This review will therefore focus on the
IIIb/IIIc splice variants, their biological function, and the
regulation of their formation especially in cancer. It will also
describe novel methods for in vitro and in vivo monitoring.
2. Structure and Function of FGFRs
2.1. Expression and Splice Variants. The FGFR-genes consist
of up to 20 exons that together code for a highly conserved
protein domain structure [9, 10]. Each of the single FGFR2 Journal of Nucleic Acids
Table 1: Ligand-binding pattern of FGFR IIIb and IIIc isoforms [8].
Receptor
Ligands binding
IIIb IIIc
FGFR1 FGF1, FGF2, FGF3, FGF10, FGF22
FGF1, FGF2, FGF4, FGF5, FGF6, FGF8,
FGF9, FGF16, FGF17, FGF18, FGF20,
FGF21, FGF23
FGFR2 FGF1, FGF3, FGF7, FGF10, FGF22
FGF1, FGF2, FGF4, FGF5, FGF6, FGF8,
FGF9, FGF16, FGF17, FGF18, FGF20,
FGF21, FGF23
FGFR3 FGF1, FGF9, FGF16
FGF1, FGF2, FGF4, FGF5, FGF6, FGF8,
FGF9, FGF16, FGF17, FGF18, FGF20,
FGF21
7 8 9
IgI
IgI
IgII
IgII
IgIIIb
IgIIIc
TM
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Kinase
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Figure 1: Schema splicing IIIb/IIIc. The extracellular domains of
FGFRs consist of 3 Ig-like loops. The IgIII loops of FGFRs 1–3 are
coded for by exons 7–9. Inclusion of exons 8 and 9 are mutually
exclusive producing the IIIb and IIIc splice forms.
genes can produce diﬀerent mRNAs during the splicing pro-
cess including variable exons, thus increasing the expressed
protein diversity.
Deletion of the Ig loop I (α-loop) has been described for
FGFR1. This event creates a high-aﬃnity oncogenic FGFR-
variant that activated distinct signaling cascades [4, 11, 12].
Similarly,skippingofthemostC-terminalinhibitorydomain
of FGFR2 has been described to result in a receptor molecule
exertingtransformingactivityinhumanmammaryepithelial
cells [5].Themostcommonvariationbothindevelopmental
processes and in cancer is the alternative splicing of Ig-loop
III, however.
For the FGFRs 1–3, the Ig-loop III is encoded by two of
the three consecutive exons 7–9, producing the domains
designated IIIa, IIIb, and IIIc. The N-terminal half of Ig-
loop III consists of the IIIa-sequence while the C-terminal
half is formed by alternative usage of either the IIIb or the
IIIc sequence creating the IIIb and IIIc isoforms of each
receptor (see Figure 1 in [2, 3]). FGFR4 lacks an alternative
exon and therefore does not have IIIb/IIIc splice variants
[13]. Because the Ig-loop III is at the core of the ligand-
binding site of FGFRs, the rearrangement profoundly alters
the ligand spectrum of the receptor (Table 1). Overall the
ligand-binding pattern of the IIIb variants is much more res-
tricted than that of the IIIc variants [8].
2.2. Physiological Function of FGFRs in Development and Tis-
sue Maintenance. FGFRs serve an essential role in embry-
ology from gastrulation [14] to organogenesis as shown by
extensive studies of gene expression patterns and genetic
analysis using knock-out mouse models (reviewed in [1, 2,
15]). Knock out of several FGFs in speciﬁc mouse models
causes an embryonic lethal phenotype or death at birth due
to severe deﬁcits in organogenesis. This underlines the essen-
tial role of FGF-signaling in embryonic development that is
also mirrored with FGFR deletion. Speciﬁcally, knock-outs
of FGFRs 1 and 2 are embryonic lethal, while FGFR3 and
FGFR4 knock out mice are viable [2]. With regard to the
IIIb/IIIcsplicevariantsitisinterestingtoobservethatspeciﬁc
deletion of the exons 8 or 9 produced distinct phenotypes—
demonstrating distinct roles for each variant FGFR. For
FGFR1, deletion of exon 9 (IIIc deﬁciency) is embryonic
lethal while deletion of exon 8 leading to loss of the IIIb
variant has no obvious phenotype [16]. For FGFR2, loss of
theIIIbvariantislethalanddeletionoftheIIIccausesskeletal
malformations [17–20].
Deeper insight in the speciﬁc roles of the IIIb and IIIc
receptor variants of the FGFRs 1–3 is provided by analysis of
their distinct spatial expression patterns. Extensive studies of
mouse embryonic development demonstrate characteristic
localizations of FGFR isoforms during organogenesis. This
is observed throughout the body [17, 21] ,b u ti sb e s ti n v e s -
t i g a t e df o rb o n ea n dd e n t a ld e v e l o p m e n t[ 22, 23]. In general
the IIIb forms of FGFRs 1–3 are expressed in epithelia while
the IIIc variants are preferentially found in the mesenchyme
[21, 24]. In concert with complementary expression patterns
of FGF ligands, tissue-speciﬁc FGFRs mediate epithelial-
mesenchymal tissue crosstalk during embryonic develop-
ment. It was shown that FGFRs expressed in the epithelium
or connective tissues are activated by FGFs secreted from the
respective complementary tissue.
The distinction is best observed for FGFR2 whose
IIIb/IIIcchoiceisstrictlytissuespeciﬁc[24].Duringdevelop-
mental processes throughout the body, expression of FGF7-
family members is observed in the connective tissue. The
secreted FGF7 and/or FGF10 activate the epithelial-speciﬁc
FGFR2-IIIb to induce a morphogenetic response in theJournal of Nucleic Acids 3
epithelium [25–27]. This response includes induction of
FGFs 8, 4, or 9, secretion of the factors from the epithelial
cells and activation of IIIc-receptor variants in the mesen-
chyme [28]( Figure 2). There is some redundancy in the FGF
family so that FGFs with similar receptor aﬃnities can sub-
stitute for one another. However there are also examples of
one speciﬁc FGF being essential at an organ site and severe
phenotypes in case of a deﬁciency—for example, FGF10
in lung development (reviewed in [1, 2]). In adult tissues
the speciﬁc expression of FGFR2 variants are maintained,
enabling tissue interactions in wound healing and tissue
repair. FGFs 7 and 10 are produced by dermal cells to stimu-
late reepithelialization through a paracrine mechanism [29–
31].
For FGFR3 the distinction is less clear as isoform expres-
sion is not strictly tissue speciﬁc. While the IIIb form is res-
tricted to epithelia, the IIIc variant can be found in both the
mesenchyme and the epithelium [33]. An example is the
intestinal mucosa, whose main FGFR3 is FGFR3-IIIb [34].
In undiﬀerentiated fetal colon, expression of FGFR3-IIIc has
been observed, however [35]. FGFR3-IIIc expression would
sensitizethemucosacellstogrowthandsurvivalsignalsfrom
FGF18 [8]. This growth factor is a β-catenin target gene and
expressed in the stem cell compartment at the bottom of
colonic crypts [36, 37]. Similar observations come from the
analysis of gene expression in the LT97 adenoma cell line
we have established from human early colonic adenomas.
When the total cell population was analyzed, the presence
of FGFR3-IIIb, but not FGFR3-IIIc, could be demonstrated
[38]. However, a subsequent study revealed the presence of
a CD44-positive subpopulation with increased growth and
survival capacity within the LT97 cell population [39]. This
speciﬁc cell population overexpressed both FGFR3-IIIc and
FGF18 as compared to the CD44-negative cells (unpublished
observation).
3. ExonSwitchinginMalignantProgression
In the past several years evidence has accumulated that de-
monstrates a central role for deregulated FGF/FGFR sig-
naling in a large number of malignant tumors (for review
see [32, 40, 41]). Hyperactivation of FGFR-dependent sig-
naling can be achieved by several mechanisms, including
altered splicing of FGFRs 1–3 [32, 42]. Splice variation in
FGFRs leads to expression of mesenchyme-speciﬁc FGFRs
in epithelium-derived cancers and broadens the range of
FGFs that can stimulate tumor cells. In most instances this
enables autocrine stimulation of tumor cells by FGFs that are
secretedbytheepitheliumtostimulateconnectivetissuecells
in a normal physiologic context [8].
A FGFR2-IIIb to IIIc switch is related to increased inva-
siveness in bladder and prostate cancers [43]. In the prostate,
the switch of FGFR2 replaces an IIIb receptor variant that
exerts antitumorigenic activity [44, 45], with a protumorige-
nic IIIc receptor. It is therefore a marker of tumor progres-
sion and tumor invasiveness [42, 44, 45]. The FGFR2 IIIb
to IIIc switch is also listed among the criteria of epithelial-
mesenchymal transition (EMT) that confer a migratory,
metastatic phenotype to several advanced carcinomas (re-
viewed in [46]).
For other receptors the contrast is less clear. However,
FGFR1-IIIc has been upregulated in several carcinomas
w h e r ei ti sr e g a r d e da sas t r o n go n c o g e n e[ 47, 48]. In both
nonsmall cell lung tumors and glioblastomas, the upregu-
lated receptor permits autocrine stimulation by FGF5 [8].
The expression of FGFR1-IIIc also results in sensitivity to
growth inhibition by a dominant negative FGFR1-IIIc cons-
truct—underlining the central role of this receptor [47, 49].
In prostate cancer as well as in TGFβ-induced EMT FGFR1-
IIIc is upregulated as an independent mesenchymal marker
and the reciprocally downregulated IIIb receptor is FGFR2
[50, 51].
In colorectal cancers the reciprocally downregulated re-
ceptor is FGFR3-IIIb. Restoration of its expression inhibits
growth under some conditions [52]. The mechanism invol-
ved is defective splicing that produces a nonsense transcript
of FGFR3-IIIb, but not increased expression of FGFR3-IIIc.
Frequently, FGFR3-IIIc expression is retained similar to the
level in normal mucosa, however, which permits transduc-
tion of growth and survival signals mediated by FGF18, ex-
pressionofwhichisupregulatedincolorectalcancer[37,38].
A dominant-negative FGFR3-IIIc construct, but not the res-
pective FGFR3-IIIb mutant, inhibits growth and survival in
colorectal tumor models in vivo and in vitro and also blocks
colorectal tumor cell migration [38].
For several other tumor types investigation of FGFR
IIIb/IIIc expression patterns are still ongoing. An interesting
example was found in ovarian cancer cells most of which
express both the IIIb and the IIIc forms of FGFR 2 and 3.
Bycontrastimmortalized ovarian surfaceepithelial cellsexp-
ress mainly the IIIc forms while FGFR2-IIIb is the main re-
ceptor type in nonimmortalized ovarian epithelial cells (un-
published observation). Even though not completely under-
stood, this does indicate a high degree of plasticity in this
cell type and seems to support the hypothesis that ovarian
cancers may arise from mesenchymal ﬁmbrial cells [53].
In contrast to carcinomas, very little is known of the role
of FGF/FGFR signaling in the disease progression in soft-
tissue sarcomas (STS). To date, there are fewer than 10 pub-
lications covering any aspect of FGFR signaling in STS.
Researchishamperedbythelowincidenceofthesetumorsin
humans, so we have initiated comparative studies of STS in
humans, dogs, and cats. The dog, with an STS incidence rate
estimated to be 12-fold to 33-fold higher than the incidence
in humans [54–56], is an excellent model of spontaneously
arising sarcomas while feline injection site sarcomas may
oﬀer insight into the role of FGFR in the development of
inﬂammation-related tumors [57].
Preliminary data have been collected by our research
group from human and animal cell lines and patient tissues.
We could identify all FGFRs and their splice variants in
human and canine STS cell lines as well as in canine spon-
taneous tumor samples. Speciﬁcally, in human and canine
STS cells FGFR1-IIIc is the FGFR with the highest transcript
levels (Figure 3).
Feline sarcomas diﬀerentially express FGFRs depending
upon the underlying cause of tumor formation—that is,4 Journal of Nucleic Acids
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Figure 2: Tissue interactions mediated by IIIb/IIIc splice variants. Expression of FGFR2 variants is strictly tissue speciﬁc with the IIIb form
found in the epithelium and the IIIc form in the mesenchyme. Together with expression of splice form-speciﬁc ligands in the respective
complementary tissue, the splice variants mediate tissue interaction during embryonic development as well as in tissue maintenance and
repair. The example FGFR2 with the IIIb-speciﬁc ligands FGF7 and 10 and the IIIc-speciﬁc ligands FGF4, 8 and 9, is involved in mouse limb
development as well as in wound healing and reepithelialization in the skin [32].
injection site sarcomas versus spontaneous sarcomas (un-
published data). As these studies progress we will be able
to address the question whether STS require alterations in
FGFR expression patterns to achieve a metastatic phenotype
and whether a “switch” between the FGFR IIIc or IIIb splice
variants has an impact in this process.
4. Exogenous Regulation of the IIIb/IIIcSwitch
Expression proﬁling in both cell lines and tissues indicates
that the splicing choice for FGFR-IIIb and IIIc variants is
strictly regulated. For FGFR2, the choice appears mutually
exclusive and maintained even in the absence of a functional
alternative exon [59]. This strict expression pattern is also
supported by the observation that the splice switch resulting
in more aggressive prostate and bladder tumors is also
mutually exclusive [42]. Based on the strong tissue speciﬁcity
and mutual exclusivity, this splice variant switch is regarded
as one of the hallmarks of EMT [46]. As such, it is correlated
with all the complex alterations producing EMT—activation
of transcription factors such as snail, loss of E-cadherin,
and upregulation of the WNT pathway [60, 61]. The splice
decision may therefore be subject to regulation by any of
the factors inducing EMT—transforming growth factor β
(TGFβ), WNT signaling, and activation of tyrosine kinase
receptors, for example, by hepatocellular growth factor
(HGF), or FGF family members [62, 63]. It has not yet been
ascertainedthatthesplicechoiceisacauseorconsequenceof
EMT.
Two pieces of information exist that link FGF signaling
itself with alternative splicing. (1) In the prostate there are
indications that loss of FGFR2-IIIb stimulation by its ligand
FGF7contributestotheswitch—indicatingthattheactivated
receptor reinforces its own expression [64]; (2) in NBT-IIJournal of Nucleic Acids 5
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Figure 3: Expression patterns of FGFR1–3 IIIb and IIIc exons in
human and canine STS cells. Preliminary data with quantitative
real-time RT-PCR indicate that FGFR1-IIIc demonstrate lowest
cycle threshold (Ct) values and thus is expressed strongest in canine
STS tumors (n = 13) and STS cell lines (n = 7) originated from
human STS tumors [58]. Bars and error bars represent mean with
SEM.
ratbladdercarcinomacellsandSVK14humankeratinocytes,
exogenous FGF1 or FGF2 induced an FGFR2 IIIb/IIIc switch
[65].
Isoform expression patterns indicate that the choice is
made diﬀerently, or at least not as stringently, for FGFRs 1
and 3—with FGFR1-IIIc being upregulated in carcinomas
without a concomitant loss of the IIIb variant [47, 48]a n d
both FGFR3 variants being expressed in epithelia [33, 35].
This leaves open the question whether regulation of splicing
is achieved by similar mechanisms for all 3 receptors.
In this context it is interesting that downregulation of
FGFR3-IIIb expression in colorectal carcinoma cells is medi-
ated by aberrant splicing that produces out-of-frame non-
sense transcripts [66]. There is no concomitant upregula-
tion of FGFR3-IIIc but an inverse relationship has been ob-
served with FGFR1-IIIc and FGFR3-IIIb expression. siRNA-
mediated FGFR1-IIIc knock down induced FGFR3-IIIb exp-
ressionwhileFGFR3-IIIboverexpressionsuppressedFGFR1-
IIIc [52].
5. Regulation of the IIIb/IIIcSwitchby
Endogenous Factors
At the transcript level, regulation of splicing is achieved by
auxiliary cis-elements that bind regulatory proteins to either
enhance or silence splicing of adjacent exons [67]. The cis-
elements are thought to consist of short, conserved RNA
sequences of typically 10 nucleotides in length that bind reg-
ulatory proteins with splicing enhancer and silencer proper-
ties. These elements can be located either in exons or introns
and act alone or in clusters [68]. In addition, some silencers
create secondary structures in the pre-mRNA that hinder
recognition of neighboring splicing enhancers by regula-
tory proteins [69].
Most known splicing regulators are RNA-binding pro-
teins (RBP), such as the serine/arginine-rich (SR) and het-
erogeneous nuclear ribonucleoprotein (hnRNP) family of
proteins. These RBPs are fairly ubiquitously expressed, albeit
with some diﬀerences in expression between tissues [70].
Detailed molecular characterization and structural modeling
of the spliceosome and the analyses of RNA regulatory ele-
ments may help to clarify the complexity of alternative spli-
cing regulation.
For FGFR2 exon IIIb and exon IIIc splicing, previous
studies identiﬁed a number of auxiliary cis-elements and
RPBs that regulate the splice event ([71, 72] and references
therein). In general the hnRNP H family of proteins has been
shown essential for activation of exon inclusion, but in case
of FGFR2 exon IIIc these proteins have been identiﬁed as
silencers that repress exon inclusion [72]. This gene and con-
text dependence of hnRNP function suggests that a complex
series of RNA-protein and protein-protein interactions are
involved in exon inclusion or exclusion. The details of these
interactions remain to be discovered.
A genome-wide high-throughput cDNA overexpression
screen identiﬁed additional splicing factors that promote
FGFR2 exon IIIb expression [73]. Among the splicing factors
identiﬁed were two paralogous epithelial cell-type-speciﬁc
RBPs termed epithelial splicing regulatory proteins 1 and 2
(ESRP1 and ESRP2) that are essential tissue-speciﬁc regula-
tors of FGFR2 splicing. Furthermore, ESRP1/2 do not only
regulate FGFR2 splicing, but a whole set of genes involved in
EMT that induce the striking cellular changes—speciﬁcally
loss of cell-cell adhesion and polarity and gain of migratory
and even invasive properties. Overexpression and knock-
down experiments indicate that their regulation is suﬃcient
to induce EMT/MET-related splice patterns [74, 75]. As des-
cribed above, EMT can be initiated, ampliﬁed, and modu-
lated by overlapping signaling pathways like WNT and TGF-
β viageneexpressionchangesthatledtothecells’phenotypic
transitions [74, 75]. Recently ESRP1/2 have been shown to
act as mastermind splice regulator, sproviding an additional
layer of gene regulation that contributes to shape the EMT
process [74, 75]. The answer as to how they are targeted by
EMT-inducing pathway has not been reported to date.
Sequence and experimental analyses generated a predic-
tive “RNA map” in which binding of ESRP1/2 either within
or 5  upstream of an alternative exon leads to exon skipping,
whereas binding to the downstream intron leads to exon
inclusion [74]. Applying such an “RNA map” on sequences
of all FGFR IIIb and IIIc variants from human and other
species, like dog and cat, may predict similar splicing regu-
lation by ESRP1/2 as observed for FGFR2 exon IIIb (see
Figure 3 in [74]). Such results must be validated by exper-
iments with tumor cells of epithelial and mesenchymal
origin that clearly demonstrate a connection between exon
IIIb/IIIc usages of all FGFRs and expression of ESRP1/2 to
address whether splicing is regulated by similar mechanisms
for all 3 receptors. Indeed, our own observations indicate
that IIIb/IIIc selection for all FGFR is similar in soft-tissue
sarcoma of human and canine origin (Figure 3).6 Journal of Nucleic Acids
Emerging information on thetopic ofalternativesplicing
control intimately links splicing of constitutive and alterna-
tive exons with transcription [76]. Evidence suggests that
transcriptional modulation of promoters via various stimuli
controls not only the production but also changes the exon
content of the gene products [77]. Furthermore, noncoding
RNAs (ncRNAs), chromatin structure, and histone modiﬁ-
cations impact on alternative splicing regulation, suggesting
that they deserve a more thorough investigation with regard
to the mechanisms of splice choices [78, 79]. Epigenetic
changes and ncRNAs determine not only what parts of
the genome are expressed but also how they are spliced,
and therefore add additional complexity on this topic.
Such mechanisms may apply to FGFR splicing regulation,
althoughreportsstudyingtheFGFR2and3promoterscould
not identify a correlation between a change in IIIb and IIIc
splicing with transcription or epigenetic regulation [80, 81].
6. Novel Methods for In Vitro and
In Vivo Research
Research analyzing alternative splicing events has changed
over the past decade to a genome-wide scale for deciphering
the regulatory networks [82–84]. Before completion of the
human genome project, most approaches were based gene
by gene on RT-PCR, sequencing, and comparison with exis-
tinginformationinsequencedatabases.Wedidusesuchstra-
tegies applying standard and quantitative RT-PCR to assess
exon IIIb and IIIc transcripts for FGFR in human tissue
material and tumor cell lines of several tumor types. For
mechanistic studies using in vitro tumor models we have
developed splice variant speciﬁc tools for both ectopic gene
expression and knock down [38, 47, 49, 85].
For analyses of material from other species such as
canine, we performed in silico analyses to locate orthologous
FGFR and developed speciﬁc PCR assays that enabled the
expressionstudiesdescribedabove.Inthecat,whosegenome
is not yet completely sequenced, we initially sequenced the
four FGFRs from genomic DNA, and determined the pres-
ence of the IIIb/IIIc splice variants based upon sequence
homology, direct sequencing of expressed transcripts, and
splice-variant speciﬁc RT-PCR.
Recent technical innovations have facilitated the inves-
tigation of alternative splicing at a global scale [83]. Splice-
sensitive microarray platforms and deep sequencing allow
quantiﬁcationoflargenumbersofalternativesplicingevents.
Global analyses of the targets of RBP combined with com-
putational analyses are beginning to reveal the regulatory
networks,theso-called“RNAmaporRNAcode”thatunder-
lies tissue-speciﬁc and developmentally regulated alternative
splicing, with potential dysregulation in cancer.
FortheFGFR,amoretraditionalapproachtostudyalter-
native splicing regulation in vitro and in vivo was based on
FGFR2 minigene models and revealed cis and trans factors
importantforsplicingregulation(reviewedin[71,72]).Such
models have been used for successful high-throughput
screening of novel genes that encode splicing regulatory pro-
teins [73]. More recently such minigene constructs have
been developed to function as IIIb/IIIc alternative splicing
reporters that produce diﬀerent luminescent and ﬂuorescent
proteins depending on inclusion or exclusion of a speciﬁc
exon [86–88]. Precise protocols for the use of such reporter
in transgenic mice are already available to clarify IIIb/IIIc
alternative splicing in vivo [89]. Similar bichromatic splic-
ing reporters expressing two diﬀerent ﬂuorescent proteins
for FGFR2 variants with potential possibilities for future
modiﬁcations are brieﬂy described (Figure 4). Such reporter
systems depending on the inclusion or exclusion of the IIIc
exon of FGFR2 contributed to the detection of both variants
withinsinglecancercellsinvitro[90,91].Thissplicingrepor-
ter system was developed and used in tumor cell models for
prostate cancer in rat and was a powerful tool which helped
to identify the epithelial plasticity and malignant ﬁtness in
tumorxenografts[90].Newersplicereportersystemsinclude
the complete genomic mouse FGFR2 sequences (around
3.7kb) of the two alternative IIIb and IIIc exons ﬂanked
by their upstream and downstream exons with introns in
between and allowed the simultaneous detection of alter-
native exon usage in vitro and in vivo [92]. Applying this
reporter system to transgenic mice and tumor cell lines
revealed the evolutionally conserved switching mechanisms
for the FGFR2 tissue-speciﬁc alternative splicing. Further
development of this model will eventually permit assessment
of the dynamics of analogous events in FGFR1 and FGFR3
processing (Figure 4). Eventually, reporter systems can be
combined in tumor cell models using ﬂuorescent proteins
with multiple wavelength properties [93]. We have previ-
ously employed ﬂuorescent reporters in the construction
of chimeric proteins consisting of FGFR1 extracellular and
transmembrane domains tagged to enhanced green ﬂuores-
cent protein (EGFP) replacing the kinase domain. This pro-
ducedadominantnegativereceptormutantwhilepermitting
identiﬁcation of cells expressing the construct through the
EGFP-partofthemolecule[47,49].Basedonthisexperience,
we plan to use ﬂuorescence reporters for analysis of IIIb/IIIc
splicing in tumor cells. These tumor cell models have the
advantage of monitoring the dynamics of splicing regulation
with single-cell resolution, to identify essential regulation by
exogeneous and endogeneous factors and to follow splicing
dynamics of tumor cells during tumor progression.
7. Therapeutic Options
7.1. Targeting FGFR Splice Variants. During the past few
years most FGFRs have been identiﬁed as targets for cancer
therapy, whose blockade by genetic or chemical means in-
hibits tumor growth (see reviews [40, 94]). In addition,
blockade of FGFR-dependent signaling interferes with sur-
vival pathways that cause resistance to standard therapies,
and combining FGFR inhibition with standard therapeutics
can result in synergistic eﬀects [95–98]. Current inhibitor-
based approaches targeting FGFRs frequently are also active
against VEGFR and/or PDGFR [15, 32]. Targeting speciﬁc
splice variants is not currently possible with small molecule
inhibitors although it may be a promising approach in
tumors that have upregulated an oncogenic FGFR-isoform.
This degree of speciﬁcity can only be achieved by genetic
constructs, isoform-speciﬁc antibodies, or ligand traps. OurJournal of Nucleic Acids 7
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Figure 4: IIIb/IIIc splice reporter systems. Schematic of bichro-
matic ﬂuorescence reporter constructs for IIIc (a) and IIIb/IIIc (b)
analyses with adaptations from [90] and [92]. The reporter genes
are positioned downstream of the splicing cassette (bold) in two
diﬀerent reading frames, each containing an individual stop codon.
Inclusion of exon IIIc (and for b simultaneous skipping of IIIb)
of FGFR2 results in a fusion protein in frame with EGFP (green)
ending at stop codon 2. Skipping of this exon (and for b simultane-
ous inclusion of IIIb) results in DsRED (red) expression in another
reading frame which contains stop codon 1. Possible adaptations of
this splicing reporter system are indicated to exchange (1) species
speciﬁc orthologous sequences, (2) sequences from IIIb splice vari-
ants, (3) sequences from paralogous FGFR 1 and 3, and (4) sequen-
ces for other ﬂuorescence reporter proteins.
own eﬀorts in blocking FGFR3-isoforms in colorectal tumor
cells have demonstrated that FGFR3 blockade mediated by
dominant-negative mutant constructs or siRNA can be spe-
ciﬁcally targeted against FGFR3-IIIb or FGFR3-IIIc which
have distinctly diﬀerent biological impact depending on the
choice of target [38].
Antibody-basedtherapiesarebeingdevelopedforFGFR3
for use in bladder cancer and multiple myeloma cell models
and have been entered into clinical trials [99]. Currently
available antibodies are not splice-form speciﬁc. However,
splice-formspeciﬁcantibodiesforexperimentalusearecom-
mercially available, so the option for a therapeutic interven-
tion of such high speciﬁcity exists.
Ligand traps have been developed from the extracellular
domains of FGFRs or from soluble splice variants. They con-
tain the ligand-binding site of the respective receptor and
trap all IIIb- or IIIc-speciﬁc FGFs that signal through it (see
Figure 1). IIIc-speciﬁc ligand-traps should be suitable for
interrupting those autocrine growth factors loops that are
enabled by a IIIb/IIIc splice switch in carcinomas. Ligand
traps have been described for FGFR4 [6] and FGFR1. The
latter construct is currently in phase I clinical trials (http://
clinicaltrials.gov/ identiﬁer NCT00687505).
7.2. Targeting Inducers of EMT. Accumulating evidence sug-
gests that, beyond triggering cell migration, EMT is capable
of conferring stem-cell-like features such as enhanced tumor
cell survival and therapy resistance. Inducing factors and
pathways other than FGF include among others TGFß, EGF,
I G F ,a n dH G F( r e v i e w e di n[ 63]). All of these are regarded
as therapeutic targets for various cancers for which targeted
drugs are being developed, for example, [100]. PDGFR is
anotherdrugabletyrosinekinasethatcanbeusedtointerfere
with EMT [101].
Common down-stream mediators that have been impli-
cated in alternative splicing regulation are the kinases in the
raf-Map-kinase and the ras-PI3K-Akt pathways (reviewed in
[102,103]).Thekinaseshavebeenreportedtophosphorylate
SR proteins in a stimulus-dependent manner aﬀecting their
subcellular location and consequently their function [104,
105]. Similar activity has also been described for protein
kinase C [106] and calmodulin-dependent protein kinase
[107] suggesting that multiple signaling pathways can mod-
ulate alternative splicing in a signal/cell type speciﬁc manner.
Targeting EMT-inducing signaling pathways and cellular
kinases will not be speciﬁc for splicing events due to their
pleiotropic roles and interactions in cell regulation. A thor-
oughknowledgenotonlyofthekinases’roleinsplicingregu-
lation, but also of all their additional downstream substrates
will be an essential prerequisite for employing such strategies
[108].
7.3. Targeting the Splicing Apparatus. Based on the emerging
detailed information on the splicing apparatus described
above, targeting on the splicing process that underlies EMT
maybeaninnovativestrategyincancertherapy.Mostimpor-
tantly, it should impact not only FGFR-dependent growth
and survival signals but also all the additional pro-metastatic
alterations in EMT [46].
For this approach three diﬀerent strategies seem feasible:
(1) splice site modulation, (2) targeting of hnRNPs or SR
proteins, and (3) targeting the spliceosome in general [109].
Splice-site modulation is the most speciﬁc approach and can
be achieved directly or indirectly. Antisense oligonucleotides
targetingtheFGFRvariantspeciﬁcregulatorysequencesmay
have direct blocking activity, similar to the intronic splicing
silencer (ISS-N1) which has been shown to fully restore
SMN2 exon 7 inclusion in case of spinal muscular atrophy
[110]. This approach succeeded in correcting the harmful
eﬀects of a splice variant by remodeling the splice reaction
and may also be useful in cancer therapy. Such a strategy
depends on the identiﬁcation and validation of the exact
splicesitesinvolvedastheyarecurrentlyavailableforFGFR2.
However, extension of this approach to FGFRs 1 and 3,
whose splice choices are regulated in a slightly diﬀerent
manner, may be considered as soon as the relevant sequence
information is available.8 Journal of Nucleic Acids
Targeting the hnRNPs or SR proteins known as splice
modulators constitutes an indirect approach [109]. Several
kinasesareknowntophosphorylateSRproteins[111].Com-
pounds have been identiﬁed that target these kinases and
are able to modulate the splicing proﬁle as demonstrated for
Cdc2-like kinase family Clk/Sty [112, 113], for SR protein
kinases SRPK1/2 [114, 115], and for topoisomerase I [116–
118]. It remains to be investigated if FGFR splicing can be
targeted by this strategy.
The third approach, targeting the spliceosome in general,
is based on the fact that malignant cells have higher meta-
bolic rates than normal cells and thus require increased
splicingactivity.Therefore,theyaremoresensitivetosplicing
modulation or inhibition [109]. A series of novel micro-
bial compounds displaying antitumor activity [119]h a v e
recently been shown to directly target the spliceosome and
modify interaction of snRNP with RNA [120, 121]. After
clinical trials with the initial model compound E7107 were
suspended due to problems with the structurally highly
complex molecules, semisynthetic derivatives have now been
developed and await further study [122]. As this strategy of
directly targeting the spliceosome is not necessarily speciﬁc
fortumorcells,itdependsondeﬁningdruglevelsthatinhibit
tumors but do not aﬀect normal cells. For monitoring pur-
poses, FGFR splicing patterns might be suitable biomarkers
to assess the eﬃcacy of these novel treatment strategies for
cancer patients.
8. Conclusions
Alternative splicing of FGFRs producing IIIb/IIIc variants
haslongbeenknowntohavestrongphysiologicalandpatho-
physiological impact—speciﬁcally in tumor development
and progression. Observations on prostate, bladder, and,
lately, in colon cancer indicate that altered splice choices are
related to altered cell behavior. Speciﬁcally the IIIc isoform
was associated with more aggressive tumors, probably be
due the broader ligand speciﬁcity of this splice forms. With
FGFR2, the switch to a IIIc variant is a marker of EMT which
produces invasive, metastasizing tumors.
Comparative analysis of FGFR splice patterns in a larger
panel of malignancies should provide more insight in both
general and tumor type speciﬁc consequences of FGFR splice
choices. From this, new diagnostic/prognostic markers as
well as therapeutic targets should arise.
Over the past years exciting new tools have been devel-
oped that enable high-throughput analysis of splice variants
aswellasathoroughinvestigationofthecellularmechanisms
underlying FGFR splice choices. The cellular splice machin-
ery has been characterized in suﬃcient detail to permit
targeting not only of tumor-speciﬁc splice variants but also
of the splicing process itself for cancer therapy.
Splice-reporter constructs expressing ﬂuorescent/lumi-
nescent gene products even permit real-time observation of
splice choices in single cells in vivo and in vitro.A p p l i c a t i o n
and further development of these new tools and technologies
should help to enlighten the role of FGFR splice variants in
cancer with emphasis on malignant progression.
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